Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells

Science Translational Medicine

Volumn 8, Issue 355, 2016, Pages

  Turtle, Cameron J ^a,b   Hanafi, Laïla Aïcha ^a   Berger, Carolina ^a,b   Hudecek, Michael ^a,d   Pender, Barbara ^a   Robinson, Emily ^a   Hawkins, Reed ^a   Chaney, Colette ^a   Cherian, Sindhu ^b   Chen, Xueyan ^b   Soma, Lorinda ^b   Wood, Brent ^b   Li, Daniel ^c   Heimfeld, Shelly ^a   Riddell, Stanley R ^a,b   Maloney, David G ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Juno Therapeutics   (United States)

^d Medizinische Klinik und Poliklinik II   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ETOPOSIDE; FERRITIN; FLUDARABINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 6; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TOCILIZUMAB; TRANSFORMING GROWTH FACTOR BETA; CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR MARKER; VIDARABINE;

ADOPTIVE TRANSFER; ADULT; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; BRAIN DISEASE; BRAIN HEMORRHAGE; CANCER IMMUNOTHERAPY; CD19 SPECIFIC CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELL; CD4 CD8 RATIO; CELL EXPANSION; CHOREOATHETOSIS; CLINICAL ARTICLE; CYTOKINE RELEASE SYNDROME; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKAPHERESIS; LYMPHOCYTE DEPLETION; MALE; MUCOSA INFLAMMATION; NONHODGKIN LYMPHOMA; OPEN STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SPEECH DISORDER; TREMOR; TUMOR REGRESSION; ANALOGS AND DERIVATIVES; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL TRIAL; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE SUBPOPULATION; METABOLISM; MIDDLE AGED; SYNDROME; TRANSGENE; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; BIOMARKERS, TUMOR; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE DEPLETION; LYMPHOCYTE SUBSETS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RECEPTORS, ANTIGEN, T-CELL; SYNDROME; TRANSGENES; TREATMENT OUTCOME; VIDARABINE; YOUNG ADULT;

EID: 84988805188     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaf8621     Document Type: Article

References (39)

1. C. J. Turtle, L.-A. Hanafi, C. Berger, T. A. Gooley, S. Cherian, M. Hudecek, D. Sommermeyer, K. Melville, B. Pender, T. M. Budiarto, E. Robinson, N. N. Steevens, C. Chaney, L. Soma, X. Chen, C. Yeung, B. Wood, D. Li, J. Cao, S. Heimfeld, M. C. Jensen, S. R. Riddell, D. G. Maloney, CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J. Clin. Invest. 126, 2123-2138 (2016).
2. M. L. Davila, I. Riviere, X. Wang, S. Bartido, J. Park, K. Curran, S. S. Chung, J. Stefanski, O. Borquez-Ojeda, M. Olszewska, J. Qu, T. Wasielewska, Q. He, M. Fink, H. Shinglot, M. Youssif, M. Satter, Y. Wang, J. Hosey, H. Quintanilla, E. Halton, Y. Bernal, D. C. Bouhassira, M. E. Arcila, M. Gonen, G. J. Roboz, P. Maslak, D. Douer, M. G. Frattini, S. Giralt, M. Sadelain, R. Brentjens, Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra25 (2014).
3. R. J. Brentjens, M. L. Davila, I. Riviere, J. Park, X. Wang, L. G. Cowell, S. Bartido, J. Stefanski, C. Taylor, M. Olszewska, O. Borquez-Ojeda, J. Qu, T. Wasielewska, Q. He, Y. Bernal, I. V. Rijo, C. Hedvat, R. Kobos, K. Curran, P. Steinherz, J. Jurcic, T. Rosenblat, P. Maslak, M. Frattini, M. Sadelain, CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra38 (2013).
4. D. W. Lee, J. N. Kochenderfer, M. Stetler-Stevenson, Y. K. Cui, C. Delbrook, S. A. Feldman, T. J. Fry, R. Orentas, M. Sabatino, N. N. Shah, S. M. Steinberg, D. Stroncek, N. Tschernia, C. Yuan, H. Zhang, L. Zhang, S. A. Rosenberg, A. S. Wayne, C. L. Mackall, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet 385, 517-528 (2015).
5. S. L. Maude, N. Frey, P. A. Shaw, R. Aplenc, D. M. Barrett, N. J. Bunin, A. Chew, V. E. Gonzalez, Z. Zheng, S. F. Lacey, Y. D. Mahnke, J. J. Melenhorst, S. R. Rheingold, A. Shen, D. T. Teachey, B. L. Levine, C. H. June, D. L. Porter, S. A. Grupp, Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507-1517 (2014).
6. J. N. Kochenderfer, M. E. Dudley, S. H. Kassim, R. P. T. Somerville, R. O. Carpenter, M. Stetler-Stevenson, J. C. Yang, G. Q. Phan, M. S. Hughes, R. M. Sherry, M. Raffeld, S. Feldman, L. Lu, Y. F. Li, L. T. Ngo, A. Goy, T. Feldman, D. E. Spaner, M. L. Wang, C. C. Chen, S. M. Kranick, A. Nath, D.-A. N. Nathan, K. E. Morton, M. A. Toomey, S. A. Rosenberg, Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33, 540-549 (2015).
7. J. N. Kochenderfer, M. E. Dudley, R. O. Carpenter, S. H. Kassim, J. J. Rose, W. G. Telford, F. T. Hakim, D. C. Halverson, D. H. Fowler, N. M. Hardy, A. R. Mato, D. D. Hickstein, J. C. Gea-Banacloche, S. Z. Pavletic, C. Sportes, I. Maric, S. A. Feldman, B. G. Hansen, J. S. Wilder, B. Blacklock-Schuver, B. Jena, M. R. Bishop, R. E. Gress, S. A. Rosenberg, Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122, 4129-4139 (2013).
8. J. N. Brudno, R. P. T. Somerville, V. Shi, J. J. Rose, D. C. Halverson, D. H. Fowler, J. C. Gea-Banacloche, S. Z. Pavletic, D. D. Hickstein, T. L. Lu, S. A. Feldman, A. T. Iwamoto, R. Kurlander, I. Maric, A. Goy, B. G. Hansen, J. S. Wilder, B. Blacklock-Schuver, F. T. Hakim, S. A. Rosenberg, R. E. Gress, J. N. Kochenderfer, Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-Cell malignancies that progress after allogeneic hematopoietic stemcell transplantation without causing graft-versus-host disease. J. Clin. Oncol. 34, 1112-1121 (2016).
9. C. Berger, M. C. Jensen, P. M. Lansdorp, M. Gough, C. Elliott, S. R. Riddell, Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest. 118, 294-305 (2008).
10. L. Gattinoni, E. Lugli, Y. Ji, Z. Pos, C. M. Paulos, M. F. Quigley, J. R. Almeida, E. Gostick, Z. Yu, C. Carpenito, E. Wang, D. C. Douek, D. A. Price, C. H. June, F. M. Marincola, M. Roederer, N. P. Restifo, A human memory T cell subset with stem cell-like properties. Nat. Med. 17, 1290-1297 (2011).
11. C. Stemberger, M. Neuenhahn, F. E. Gebhardt, M. Schiemann, V. R. Buchholz, D. H. Busch, Stem cell-like plasticity of naïve and distinct memory CD8+ T cell subsets. Semin. Immunol. 21, 62-68 (2009).
12. X. Wang, C. Berger, C. W. Wong, S. J. Forman, S. R. Riddell, M. C. Jensen, Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. Blood 117, 1888-1898 (2011).
13. D. Sommermeyer, M. Hudecek, P. L. Kosasih, T. Gogishvili, D. G. Maloney, C. J. Turtle, S. R. Riddell, Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia 30, 492-500 (2015).
14. B. Savoldo, C. A. Ramos, E. Liu, M. P. Mims, M. J. Keating, G. Carrum, R. T. Kamble, C. M. Bollard, A. P. Gee, Z. Mei, H. Liu, B. Grilley, C. M. Rooney, H. E. Heslop, M. K. Brenner, G. Dotti, CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121, 1822-1826 (2011).
15. N. Singh, J. Perazzelli, S. A. Grupp, D. M. Barrett, Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Sci. Transl. Med. 8, 320ra3 (2016).
16. J. A. Fraietta, K. A. Beckwith, P. R. Patel, M. Ruella, Z. Zheng, D. M. Barrett, S. F. Lacey, J. J. Melenhorst, S. E. McGettigan, D. R. Cook, C. Zhang, J. Xu, P. Do, J. Hulitt, S. B. Kudchodkar, A. P. Cogdill, S. Gill, D. L. Porter, J. A. Woyach, M. Long, A. J. Johnson, K.Maddocks, N. Muthusamy, B. L. Levine, C. H. June, J. C. Byrd, M. V. Maus, Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood 127, 1117-1127 (2016).
17. D. L. Porter, W.-T. Hwang, N. V. Frey, S. F. Lacey, P. A. Shaw, A. W. Loren, A. Bagg, K. T. Marcucci, A. Shen, V. Gonzalez, D. Ambrose, S. A. Grupp, A. Chew, Z. Zheng, M. C. Milone, B. L. Levine, J. J. Melenhorst, C. H. June, Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med. 7, 303ra139 (2015).
18. L. Gordis, Epidemiology (Elsevier, Philadelphia, 2008).
19. C. S. Hinrichs, R. Spolski, C. M. Paulos, L. Gattinoni, K. W. Kerstann, D. C. Palmer, C. A. Klebanoff, S. A. Rosenberg, W. J. Leonard, N. P. Restifo, IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 111, 5326-5333 (2008).
20. C. A. Klebanoff, S. E. Finkelstein, D. R. Surman, M. K. Lichtman, L. Gattinoni, M. R. Theoret, N. Grewal, P. J. Spiess, P. A. Antony, D. C. Palmer, Y. Tagaya, S. A. Rosenberg, T. A. Waldmann, N. P. Restifo, IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc. Natl. Acad. Sci. U.S.A. 101, 1969-1974 (2004).
21. M. Kalos, B. L. Levine, D. L. Porter, S. Katz, S. A. Grupp, A. Bagg, C. H. June, T cellswith chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced Leukemia. Sci. Transl. Med. 3, 95ra73 (2011).
22. J. N. Kochenderfer, M. E. Dudley, S. A. Feldman, W. H. Wilson, D. E. Spaner, I. Maric, M. Stetler-Stevenson, G. Q. Phan, M. S. Hughes, R. M. Sherry, J. C. Yang, U. S. Kammula, L. Devillier, R. Carpenter, D.-A. N. Nathan, R. A. Morgan, C. Laurencot, S. A. Rosenberg, B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709-2720 (2012).
23. D. L. Porter, B. L. Levine, M. Kalos, A. Bagg, C. H. June, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733 (2011).
24. S. Ninomiya, N. Narala, L. Huye, S. Yagyu, B. Savoldo, G. Dotti, H. E. Heslop, M. K. Brenner, C. M. Rooney, C. A. Ramos, Tumor indoleamine 2, 3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood 125, 3905-3916 (2015).
25. C. J. Turtle, L.-A. Hanafi, C. Berger, T. Gooley, C. Chaney, S. Cherian, L. Soma, X. Chen, C. S. Yeung, K. Loeb, B. L. Wood, M. Hudecek, D. Sommermeyer, D. Li, K. A. Hay, S. Heimfeld, S. R. Riddell, D. G. Maloney, Rate of durable complete response in ALL, NHL, and CLL after immunotherapy with optimized lymphodepletion and defined composition CD19 CAR-T cells. J. Clin. Oncol. 34, 102 (2016).
26. S. Terakura, T. N. Yamamoto, R. A. Gardner, C. J. Turtle, M. C. Jensen, S. R. Riddell, Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. Blood 119, 72-82 (2012).
27. M. Hudecek, D. Sommermeyer, P. L. Kosasih, A. Silva-Benedict, L. Liu, C. Rader, M. C. Jensen, S. R. Riddell, The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol. Res. 3, 125-135 (2015).
28. X.Wang, W.-C. Chang, C.W. Wong, D. Colcher, M. Sherman, J. R. Ostberg, S. J. Forman, S. R. Riddell, M. C. Jensen, A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118, 1255-1263 (2011).
29. B. D. Cheson, R. I. Fisher, S. F. Barrington, F. Cavalli, L. H. Schwartz, E. Zucca, T. A. Lister; Alliance Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Goup; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; United Kingdom National Cancer Research Institute, Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J. Clin. Oncol. 32, 3059-3068 (2014).
30. S.-T. Yeh, Using trapezoidal rule for the area under a curve calculation, paper presented at the 27th SAS User's Group International Conference, Cary, NC, 2002.
31. C. Berger, M. E. Flowers, E. H. Warren, S. R. Riddell, Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 107, 2294-2302 (2006).
32. Y. Kim, J. Ponomarenko, Z. Zhu, D. Tamang, P. Wang, J. Greenbaum, C. Lundegaard, A. Sette, O. Lund, P. E. Bourne, M. Nielsen, B. Peters, Immune epitope database analysis resource. Nucleic Acids Res. 40, W525-W530 (2012).
33. C. Lundegaard, K. Lamberth, M. Harndahl, S. Buus, O. Lund, M. Nielsen, NetMHC-3.0: Accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res. 36, W509-W512 (2008).
34. M. Nielsen, C. Lundegaard, P. Worning, S. L. Lauemøller, K. Lamberth, S. Buus, S. Brunak, O. Lund, Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci. 12, 1007-1017 (2003).
35. B. Peters, A. Sette, Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics 6, 132 (2005).
36. J. Sidney, E. Assarsson, C. Moore, S. Ngo, C. Pinilla, A. Sette, B. Peters, Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries. Immunome Res. 4, 2 (2008).
37. W. J. Youden, Index for rating diagnostic tests. Cancer 3, 32-35 (1950).
38. M. Schemper, T. L. Smith, A note on quantifying follow-up in studies of failure time. Control. Clin. Trials 17, 343-346 (1996).
39. D. W. Lee, R. Gardner, D. L. Porter, C. U. Louis, N. Ahmed, M. Jensen, S. A. Grupp, C. L. Mackall, Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188-195 (2014).